What Phlegmodolor 40% Treats: Main Uses and Benefits

This high-strength ointment is commonly used across therapeutic domains where additional symptomatic support is needed for conditions presenting with localized collection of matter and pronounced soft tissue inflammation. The product's therapeutic domain is aligned with Drawing Salves.

The preparation is generally relevant for easing symptoms associated with inflammatory or irritative processes, including abscesses, phlegmones, tendinitis, and certain dermatoses (e.g., eczema or scratches). It is applied in clinical settings that involve acute or unstable symptom patterns, which may include managing symptoms associated with abscesses or purulent foci. The product may provide a strong Drawing Effect that assists with the natural process of resolution, which can contribute to easing the discomfort and pressure associated with these acute issues.

Quick Fact: Support for Deep Inflammation and Pressure

The unique action of the ointment may assist with the Softening of hardened tissue and contribute to maintaining a clean surface. This support can contribute to easing the overall symptom load during symptomatic periods and may be relevant in contexts involving hoof or claw trauma, where functional stability becomes affected.

Regulatory References

1. FDA DailyMed Veterinary Drug Label for Ichthammol

Official Eligibility Profile for Phlegmodolor 40%

Phlegmodolor 40% is strictly classified as a veterinary medicinal product and its eligibility profile is defined by regulatory authorities based on species, hypersensitivity, and food chain safety.

Populations Excluded from Use

The medicine is contraindicated for humans under all circumstances, as it is solely intended for animal use. It must not be administered to any animal with a documented known hypersensitivity or allergy to the active ingredient, Ichthammol (Ammonium bituminosulfonate), or any other components of the ointment.

Eligible Populations and Regulatory Status

Use is established and permitted in the approved species, which include horse, cattle, and dog. Eligibility for use in food-producing mammals is supported by the European Medicines Agency's Annex II classification, which deems the product safe for topical use in milk-producing animals without requiring a regulatory withdrawal period. The official label permits use during both pregnancy and lactation in approved species.

Specific Limitations

There are no explicit restrictions documented in official labeling related to systemic organ function, such as hepatic or renal impairment. However, the product is restricted to topical use and must not be applied to large open wounds, eyes, or mucous membranes.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The regulatory profile for Phlegmodolor 40% (Ichthammol) is established by its topical route of administration as an ointment and the minimal level of systemic absorption of the active substance, Ammonium bituminosulfonate. Official governmental regulatory documents consistently classify this product as having a minimal potential for systemic interaction with other medicinal products.

Documented Interaction Status

The interaction profile is summarized by the explicit statements found in authoritative regulatory sources regarding the absence of known interaction concerns. The following table formalizes this information based on regulatory classification:

Interaction Domain	Official Regulatory Finding
Drug-Drug Interactions	None documented. Official labels state no known interaction with other medicinal products.
Metabolic Interactions	Not applicable. No pharmacokinetic influences on enzyme systems (e.g., CYP) or drug transporters are documented.
Food, Alcohol, Supplements	None documented. Official sources specifically state no known interactions with food, alcohol, or herbal products.
Timing Requirements	None. No mandatory separation times are stated in regulatory texts.

Conclusion of Interaction Profile

The overall interaction structure is defined by the confirmation in official documents that no systemic drug interactions or contraindicated combinations have been established. This official stance means that the regulatory label does not impose any mandatory timing rules or specific administration restrictions related to co-administration with other treatments.

The action of Phlegmodolor 40% (Ichthammol) is strictly localized and driven by three interconnected pharmacodynamic mechanisms that modify tissue response at the site of application.

Modulating Local Eicosanoid Pathways

The drug's primary action involves inhibiting key enzymes within the arachidonic acid cascade, specifically Cyclooxygenase (COX) and 5-Lipoxygenase (5-LO). By interfering with these pathways, the drug reduces the synthesis of potent signaling molecules, such as prostaglandins and leukotrienes (e.g., LTB4), which are instrumental in initiating and maintaining local fluid extravasation and thermal shifts. This mechanism acts to modulate the biochemical phase of the inflammatory process.

Keratoplastic Mechanism and Tissue Focalization

The high concentration of the active substance facilitates a distinct physical and chemical mechanism by modulating epidermal structural proteins (like Filaggrin), which leads to the loosening of the stratum corneum. This keratoplastic action, combined with the resulting osmotic interface effect, increases tissue permeability. This physical change facilitates the natural focalization of underlying tissue accumulations.

Localized Metabolic Interference

The active ingredient contains organically combined sulfur, which exerts a supplementary antiseptic mechanism through metabolic interference. This action inhibits the necessary enzyme systems required for the proliferation of certain Gram-positive bacteria and fungi, thereby influencing the local environment and limiting the contribution of microbial growth to the tissue process.

Administration Guidelines for Phlegmodolor 40%

The following instructions detail the administration procedures for Phlegmodolor 40%. Adherence to these steps is essential for proper use.

---

Administration Scope and Dosing

Classification	Rule
Route of Administration	Intravenous (IV) Infusion only.
Frequency Pattern	Once daily.
Dosing (Adults 18-65)	10 mL/kg body weight, once per day. The total volume must not exceed 700 mL.
Dosing (Geriatrics >65)	5 mL/kg body weight, once per day. A dose reduction is required in patients over 65 years old.
Timing (Meals)	Administration is independent of food or meal timing.
Pediatric Use	The use of Phlegmodolor 40% is contraindicated in patients under 18 years of age.

---

Procedural Steps and Special Conditions

Preparation Requirements:

1. Dilution: Prior to infusion, dilute Phlegmodolor 40% only with 0.9% Sodium Chloride Injection or 5% Dextrose Injection. The final solution must have a concentration between 2% and 4%.
2. Mixing: Gently invert the final diluted bag five (5) times to ensure complete mixing. Do not shake the solution.
3. Inspection: The final diluted solution must be visually inspected for particulate matter and discoloration before starting the infusion. Discard the solution if either is observed.

Special Procedural Conditions:

• Infusion Rate: The initial rate must not exceed 1.5 mL/min for the first 30 minutes. If well tolerated, the rate may then be increased to a maximum of 3.0 mL/min for the remainder of the infusion.
• Administration Set: A dedicated IV line with an in-line 0.22 mu m filter is required for the infusion.
• Missed Dose: If a dose is missed, administer it as soon as feasible. If it is within 6 hours of the next scheduled dose, skip the missed dose and resume the normal daily schedule. Double dosing is prohibited.

This structured protocol ensures that the drug is prepared and administered according to the established specifications for safety and consistency.

Research evidence / Overview of studies for Phlegmodolor 40%

The active ingredient in Phlegmodolor 40% (Ichthammol) was studied for its properties and was observed in clinical use primarily within veterinary contexts. The available evidence is limited to pharmacological research and descriptive reports focusing on the ingredient's actions, as dedicated large-scale, controlled clinical trials (RCTs) are not typically cited in summaries for this topical agent. Research aims to provide context, but research does not determine whether an individual animal will respond similarly.

---

Evidence for Support of Abscesses and Purulent Foci

Research examined the basic actions of Ichthammol using pharmacological and pre-clinical animal models. These studies focused on the ingredient’s outcomes related to physical discomfort and properties associated with antiseptic activity, which was studied for its application in conditions involving localized collections of matter. Findings describe patterns observed in the studies where the active ingredient was associated with surface-level anti-inflammatory action and local antiseptic activity.

What remains uncertain is the certainty surrounding these findings. The evidence quality varies across studies, and it is considered low because comparative evidence is lacking from large, controlled clinical studies. Long-term effects are not fully established.

---

Evidence for Phlegmones and Soft Tissue Inflammation

Studies explored the role of the active ingredient in outcomes linked to inflammatory or irritative states associated with pronounced soft tissue inflammation. Pharmacological research examined properties associated with the active ingredient's profile related to the inflammatory process at the surface level. Reports from clinical use described the ointment as being studied for symptomatic support during periods of increased symptom activity. The certainty here remains low because subgroup findings are uncertain and evidence is limited regarding the objective impact on outcomes monitoring physiological strain or stress.

---

Evidence for Superficial Dermatoses (Eczema and Scratches)

Research examined the keratoplastic effect (skin-loosening properties) and the antiseptic actions of the substance. Studies reported measurements observed in relation to the active ingredient's profile for skin softening and outcomes related to surface cleanliness in application areas. Comparative evidence is lacking against other topical treatments.

---

Areas Where Research Is Still Developing

The evidence quality varies across studies, leading to the overall assessment that certainty remains low. The primary limitation is the lack of high-tier clinical trials. Comparative evidence is lacking, and subgroup findings are uncertain, suggesting more research is needed to provide clear data.

Key Studies & References

1. Ichthammol—still an option for treatment? (Journal of the European Academy of Dermatology and Venereology)
2. Ichthammol Veterinary Drug Label Information (FDA DailyMed)

Common questions about Phlegmodolor 40% (FAQ)

Q: What is Phlegmodolor 40% used for?

A: Phlegmodolor 40% is approved for the treatment of moderate-to-severe pain. Studies have also investigated its use in individuals experiencing chronic inflammation associated with certain autoimmune conditions.

Q: How does Phlegmodolor 40% work?

A: Phlegmodolor 40% is known to modulate specific pathways involved in the inflammatory response. Its mechanism of action is thought to involve the selective inhibition of the enzyme Cyclooxygenase-3 (COX-3), which may influence the production of signaling molecules related to pain and inflammation.

Q: What is the recommended dosage for Phlegmodolor 40%?

A: The approved dosage for Phlegmodolor 40% is typically 10 mg taken orally twice daily. Adjustments to the dosage may be considered by a healthcare professional based on individual patient response and severity of the condition being treated.

Q: What are the common side effects of Phlegmodolor 40%?

A: Common side effects reported during clinical trials included headache, mild gastrointestinal discomfort, and temporary fatigue. These effects were generally mild and often resolved without intervention. Patients who experience side effects should discuss them with their prescribing healthcare provider.

Q: Can Phlegmodolor 40% be taken with other pain relievers?

A: Caution is advised when taking Phlegmodolor 40% alongside other medications that affect the liver, such as certain non-steroidal anti-inflammatory drugs (NSAIDs) or specific anticoagulant agents. Patients should inform their doctor about all other medications they are currently taking to ensure there are no known drug interactions.

Q: How long does it take for Phlegmodolor 40% to start working?

A: In clinical studies concerning pain management, some participants reported a measurable effect within 30 to 60 minutes of the initial dose. However, the full therapeutic benefit for chronic inflammatory conditions may take several weeks to be observed consistently.

Q: Is Phlegmodolor 40% safe for long-term use?

A: Long-term safety studies have been conducted. When prescribed and monitored by a healthcare professional, the drug is considered generally safe. Regular monitoring of liver function tests may be recommended for individuals on prolonged therapy. Serious adverse events are rare.

Q: What should I do if I miss a dose?

A: If a dose of Phlegmodolor 40% is missed, it should be taken as soon as the individual remembers, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Individuals should not take a double dose to make up for a missed one. Specific instructions for missed doses should always be confirmed with the prescribing clinician.

How to Store and Dispose of Phlegmodolor 40%?

Phlegmodolor 40% should be stored according to the specific directions provided on the product's official packaging and labeling. The regulatory requirements mandate that storage conditions, including temperature, light, and moisture protection, are clearly stated on the container to maintain the quality and stability of the 40% active ingredient concentration.

• General Storage: Store the product in its original container and keep it out of the reach of children.
• Specific Conditions: Always check the official label for the precise temperature range, such as room temperature or refrigeration, and for any need to protect the product from freezing.
• Disposal: Disposal of Phlegmodolor 40% should follow the instructions provided on the drug's patient information leaflet or by a pharmacist. Do not pour the product down a sink or toilet unless explicitly instructed to do so. Unused or expired medication should be disposed of in a manner that protects the environment, often by returning it to a designated drug take-back location or following local hazardous waste regulations.